Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2. (4th July 2021)

• Record Type: Journal Article
• Authors: Grandjean, Louis; Saso, Anja; Torres Ortiz, Arturo; Lam, Tanya; Hatcher, James; Thistlethwayte, Rosie; Harris, Mark; Best, Timothy; Johnson, Marina; Wagstaffe, Helen; Ralph, Elizabeth; Mai, Annabelle; Colijn, Caroline; Breuer, Judith; Buckland, Matthew; Gilmour, Kimberly; Goldblatt, David
• Is Part Of: Clinical infectious diseases. Volume 74:Number 7(2022)
• Page Start: 1220
• Page End: 1229
• Publication Date: 2021-07-04
• Subjects: immunity -- serology -- antibody -- ELISA -- kinetics -- neutralization -- SARS-CoV-2 -- COVID-19 -- virus -- nucleoprotein -- spike protein; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab607
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been shown to neutralize the virus in vitro and prevent disease in animal challenge models on reexposure. However, the current understanding of SARS-CoV-2 humoral dynamics and longevity is conflicting. Methods: The COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) prospectively enrolled 3679 healthcare workers to comprehensively characterize the kinetics of SARS-CoV-2 spike protein (S), receptor-binding domain, and nucleoprotein (N) antibodies in parallel. Participants screening seropositive had serial monthly serological testing for a maximum of 7 months with the Meso Scale Discovery Assay. Survival analysis determined the proportion of seroreversion, while 2 hierarchical gamma models predicted the upper and lower bounds of long-term antibody trajectory. Results: A total of 1163 monthly samples were provided from 349 seropositive participants. At 200 days after symptoms, >95% of participants had detectable S antibodies, compared with 75% with detectable N antibodies. S antibody was predicted to remain detectable in 95% of participants until 465 days (95% confidence interval, 370–575 days) using a "continuous-decay" model and indefinitely using a "decay-to-plateau" model to account for antibody secretion by long-lived plasma cells. S-antibody titers were correlated strongly with surrogate neutralization in vitro ( R 2 = 0.72). N antibodies, however, decayed rapidly with a half-life of 60 days (95% confidence interval, 52–68 days). Conclusions: The Co-Stars data presented here provide evidence for long-term persistence of neutralizing S antibodies. This has important implications for the duration of functional immunity after SARS-CoV-2 infection. In contrast, the rapid decay of N antibodies must be considered in future seroprevalence studies and public health decision-making. This is the first study to establish a mathematical framework capable of predicting long-term humoral dynamics after SARS-CoV-2 infection. Clinical Trials Registration: NCT04380896. Abstract : We demonstrate persistence of spike protein and decay of nucleoprotein antibody in serial samples from 349 patients up to 200 days after severe acute respiratory syndrome coronavirus 2 infection and provide a mathematical modeling framework to predict long-term immune responses.